Ibuprofen versus mecillinam for uncomplicated cystitis--a randomized controlled trial study protocol

BMC Infect Dis. 2014 Dec 17:14:693. doi: 10.1186/s12879-014-0693-y.

Abstract

Background: Although uncomplicated cystitis is often self-limiting, most such patients will be prescribed antibiotic treatment. We are investigating whether treatment of cystitis with an NSAID is as effective as an antibiotic in achieving symptomatic resolution.

Methods/design: This is a randomized, controlled, double blind trial following the principles of Good Clinical Practice. Women between the ages of 18 to 60 presenting with symptoms of uncomplicated cystitis are screened for eligibility. 500 women from four sites in Norway, Sweden and Denmark are allocated to treatment with 600 mg ibuprofen three times a day or 200 mg mecillinam three times a day for three days. Allocation is conducted using block randomization. The primary outcome is the number of patients who feel cured by day four as recorded in a diary. Adverse events will be handled and reported in accordance with Good Clinical Practice.

Discussion: If treatment of uncomplicated cystitis with ibuprofen is as effective as mecillinam for symptom relief, we can potentially reduce the use of antibiotics on a global scale.

Trial registration: EudraCTnr: 2012-002776-14. ClinicalTrials.gov: NCT01849926.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Amdinocillin / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Clinical Protocols
  • Cystitis / drug therapy*
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Ibuprofen / therapeutic use*
  • Middle Aged
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Amdinocillin
  • Ibuprofen

Associated data

  • EudraCT/2012-002776-14
  • ClinicalTrials.gov/NCT01849926